1. The current statement from the Biden administration states that patients may be eligible in near future for a 3rd dose of mRNA COVID-19 injection how many months after second dose?
A. 2
B. 4
C. 8
D. 12
E. Unsure
2. Which of the following patient groups was at highest risk for myocarditis from mRNA vaccines according to the July MMWR report cited in this program?
A. Females age 12–29
B. Females age 30 and older
C. Males age 12–29
D. Males age 12–17
E. Unsure
3. Guillain-Barré syndrome in people receiving which of the following COVID-19 vaccines necessitated an update to its FDA-authorized fact sheet?
A. Moderna
B. Pfizer
C. Janssen/Johnson & Johnson
D. Novartis
E. Unsure
4. What percentage of patients tolerated second doses of mRNA vaccines (defined as no or mild reaction) after an initial allergic reaction in a recent study published in JAMA?
A. 25%
B. 50%
C. 75%
D. 100%
E. Unsure
5. Which of the following mixing of vaccines has demonstrated increased neutralization activity against SARS-CoV-2?
A. BNT162b2 followed by mRNA-1273
B. mRNA-1273 followed by BNT162b2
C. ChAdOx1 nCOV-19 followed by mRNA-1273
D. ChAdOx1 nCOV-19 followed by BNT162b2
E. Unsure
6. Which of the following benefits was demonstrated in a recent New England Journal of Medicine study regarding convalescent plasma?
A. Decreased time to hospitalization
B. Decreased mortality
C. Decreased progression to intensive care
D. None of these
E. Unsure
7. According to recently revised COVID-19 treatment guidelines from the National Institutes of Health, which of the following monoclonal antibodies is recommended and can be administered subcutaneously for postexposure prophylaxis?
A. Casirivimab
B. Casivivimab plus imdevimab
C. Adalinumab
D. Sotrovimab
E. Unsure
8. Which of the following repurposed antidepressants has shown promise in preventing progression of COVID-19 disease?
A. Fluoxetine
B. Sertraline
C. Amitriptyline
D. Fluvoxamine
E. Unsure
9. In studies with hamsters, how have intranasal COVID-19 vaccines affected viral loads in the nasal passages compared with intramuscular dosage forms?
A. Less amounts of infectious virus
B. More amounts of infectious virus
C. Similar amounts of infectious virus
D. Studies were stopped early due to worsened toxicity in intranasal arm of study
E. Unsure
10. Which of the following currently studied oral options for COVID-19 is a ribonucleoside analogue that inhibits replication of SARS-CoV-2?
A. PF-07321332
B. S-217622
C. Molnupiravir
D. Minapiravir
E. Unsure
Evaluation Questions
11. To what extent did the program meet objective #1?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
12. To what extent did the program meet objective #2?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
13. Rate the effectiveness of how well the program related to your educational needs:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
14. Rate how well the active learning strategies (questions, cases, discussions) were appropriate and effective learning tools:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
15. Rate the quality of the faculty:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
16. Rate the effectiveness and the overall usefulness of the material presented:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
17. Rate the appropriateness of the examination for this activity:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
18. Rate the effectiveness of how well the activity related to your practice needs:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
19. Rate the effectiveness of how well the activity will help you improve patient care:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
20. Will the information presented cause you to change your practice?
A. Yes
B. No
21. Are you committed to making these changes?
A. Yes
B. No
22. As a result of this activity, did you learn something new?
A. Yes
B. No
23. What is your practice setting or area of practice?
A. Community Pharmacy/Independent
B. Community Pharmacy/Chain
C. Hospital/Health Systems
D. Administrative/Pharmacy Director
E. Critical Care Pharmacy
F. Long-term Care
G. Managed Care/PBM
H. Oncology
I. Specialty Pharmacy
J. Industry/Manufacturing
24. How many years have you been in practice?
A. <5
B. 5 – 10
C. 11 – 20
D. >20